Y Intercept Hong Kong Ltd bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,817 shares of the biopharmaceutical company's stock, valued at approximately $1,506,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Agios Pharmaceuticals as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. State Street Corp lifted its stake in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after buying an additional 216,484 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at $33,767,000. BNP Paribas Financial Markets lifted its stake in shares of Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after buying an additional 1,570 shares in the last quarter. FMR LLC lifted its stake in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after buying an additional 33,546 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at $892,000.
NASDAQ AGIO opened at $35.19 on Wednesday. Agios Pharmaceuticals, Inc. has a 52-week low of $27.14 and a 52-week high of $62.58. The company has a 50-day simple moving average of $34.01 and a 200 day simple moving average of $42.92. The company has a market capitalization of $2.02 billion, a PE ratio of 3.10 and a beta of 0.88.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.
A number of research firms have weighed in on AGIO. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday. They issued a "buy" rating and a $58.00 price objective on the stock. Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Scotiabank increased their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $56.57.
Read Our Latest Analysis on Agios Pharmaceuticals
In related news, insider Tsveta Milanova sold 2,804 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.93% of the stock is currently owned by corporate insiders.
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.